Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Research on Biomarkers for Early Therapeutic Response

Inclusion Criteria

• •patient aged \> 18 years old
• •patient with metastatic non-small cell lung cancer with marketing authorisation criteria for immunotherapy
• •preserved overall condition (Performans Status 1)
• •signed informed consent
• •patient with healthcare insurance
• •patient with oxygen therapy or invasive ventilation
• •patient unable to perform a slow vital capacity
• •systemic corticosteroid therapy more than 10 mg per day of prednisone equivalent
• •previous treatment with immunotherapy
• •dermatological therapy interfering with sweat collection (psoriasis, irritant dermatitis, for instance)
• •Patient deprived of liberty by judicial or administrative decision